Head to Head Analysis: 180 Life Sciences (NASDAQ:ATNF) & Harmony Biosciences (NASDAQ:HRMY)

180 Life Sciences (NASDAQ:ATNF) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

7.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 47.7% of Harmony Biosciences shares are owned by institutional investors. 73.5% of 180 Life Sciences shares are owned by insiders. Comparatively, 28.8% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares 180 Life Sciences and Harmony Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
180 Life Sciences N/A -310.67% -102.68%
Harmony Biosciences 9.86% 66.92% 19.75%

Analyst Ratings

This is a breakdown of recent ratings for 180 Life Sciences and Harmony Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences 0 0 1 0 3.00
Harmony Biosciences 0 0 1 0 3.00

180 Life Sciences currently has a consensus price target of $11.00, suggesting a potential upside of 89.33%. Harmony Biosciences has a consensus price target of $43.00, suggesting a potential upside of 15.34%. Given 180 Life Sciences’ higher possible upside, equities research analysts plainly believe 180 Life Sciences is more favorable than Harmony Biosciences.

Earnings & Valuation

This table compares 180 Life Sciences and Harmony Biosciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
180 Life Sciences N/A N/A -$10.88 million N/A N/A
Harmony Biosciences $159.74 million 13.30 -$36.94 million $0.21 177.52

180 Life Sciences has higher earnings, but lower revenue than Harmony Biosciences.

Summary

Harmony Biosciences beats 180 Life Sciences on 5 of the 8 factors compared between the two stocks.

About 180 Life Sciences

180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. It operates as a clinical-stage biotechnology company focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded on September 7, 2016 and is headquartered in Palo Alto, CA.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Receive News & Ratings for 180 Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 180 Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.